English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA new study led by researchers from Moffitt Cancer Center, in collaboration with investigators from the University of Michigan, shows that artificial intelligence (AI) can help doctors make better decisions when treating cancer. However, it also highlights challenges in how doctors and AI work together. The study, published in Nature Communications, focused on AI-assisted radiotherapy for non-small cell lung cancer and hepatocellular carcinoma (liver cancer).
Tag: Cancer Treatment
Ralph Weichselbaum, MD, appointed University of Chicago Health System leader for Radiation and Cellular Oncology
In his expanded health system role, Ralph Weichselbaum leads efforts to bring radiation therapy to patients at the University of Chicago Medicine, including in Chicago’s suburbs and in Northwest Indiana.
Roswell Park Study Reveals How Venetoclax Boosts Immune Response to CAR T for Chronic Lymphocytic Leukemia
Research out of Roswell Park Comprehensive Cancer Center has shed light on how the drug venetoclax (brand name Venclexta) works synergistically with CAR T-cell immunotherapy to combat chronic lymphocytic leukemia (CLL), the most common type of leukemia in the U.S. Matthew Cortese, MD, MPH, Assistant Professor of Oncology in Roswell Park’s departments of Medicine and Cancer Genetics & Genomics, is first author of the study, which he will present during an oral abstract session today at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California.
Keto diet metabolite may power up CAR T cells to kill cancer
A simple dietary supplement may provide a new approach to boost CAR T cell function, according to a study from researchers in the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine’s Abramson Cancer Center, presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 4).
Late-breaking abstract at SUO: Novel oncolytic immunotherapy shows promise for patients with bladder cancer
A Mayo Clinic Comprehensive Cancer Center researcher will share findings from a late-breaking abstract at the 2024 Society of Urologic Oncology Annual Meeting. The study demonstrated a potentially effective treatment for patients with bladder cancer who no longer respond to the common therapy, Bacillus Calmette-Guérin (BCG).
Research reveals how fructose in diet enhances tumor growth
Dietary fructose promotes tumor growth in animal models of melanoma, breast cancer and cervical cancer. However, fructose does not directly fuel tumors, according to the study published Dec. 4 in the journal Nature. Instead, WashU scientists discovered that the liver converts fructose into usable nutrients for cancer cells, a compelling finding that could open up new avenues for care and treatment of many different types of cancer.
UT Southwestern brings first-of-its-kind radiation oncology to new $177M campus in Fort Worth Medical District
To meet the growing demands for cancer treatment in Tarrant County and surrounding areas, UT Southwestern Medical Center is expanding its cancer services in the Fort Worth Medical District with construction of a new two-story Radiation Oncology campus that will house the city’s first MRI-guided precision radiation treatment.
Argonne to explore novel ways to fight cancer and transform vaccine discovery with over $21 million from ARPA-H
Argonne has received up to $21 million from ARPA-H to use AI and supercomputing in two projects: one targeting hard-to-treat tumors, and another aiming to create vaccines for multiple viral threats, including cancer and pandemics.
Treatment advances, predictive biomarkers stand to improve bladder cancer care
Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk localized, muscle-invasive disease, according to a New England Journal of Medicine editorial published by Matthew Milowsky, MD, FASCO, a bladder cancer expert at UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center.
MD Anderson launches Institute for Cell Therapy Discovery & Innovation to deliver transformational new therapies
The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation, which will build upon longstanding MD Anderson clinical and research expertise to lead the world in developing and advancing impactful cell therapies for patients in need.
Novel Prostate Cancer Treatment Increases Overall Survival Rates for Late-Stage Prostate Cancer Patients
A global study of a combination drug therapy, led by an investigator at Huntsman Cancer Institute, has shown improved overall survival rates for metastatic prostate cancer compared to standard treatments.
Assessment and Management of Lymphatic Pain in Breast Cancer Survivors
Lymphatic pain refers to co-occurring pain, or sensations of aching, soreness, tenderness, and swelling due to fluid accumulation. Lymphatic pain impairs breast cancer survivors’ physical function, emotional and overall health. Lymphatic pain usually occurs in the ipsilateral body or upper limb following breast cancer treatment. Precision assessment to distinguish lymphatic pain from other different types of pain is essential.
Harnessing Protons to Treat Cancer
Radiation therapy techniques have been used for more than a century to treat cancers. Physicists in the Radiation Detector and Imaging group and associated with the Biomedical Research & Innovation Center (BRIC) at Jefferson Lab are launching a study into how best to advance safer types of radiation therapy. BRIC scientists plan to evaluate the ability of accelerator-based proton therapy to replace radioactive isotope-derived treatments.
Gut Microbiome Health Tech Innovator, Ixcela Launches Virtual Clinic to Ease Cancer Symptoms After Landmark Roper St. Francis Healthcare Pilot
In recognition of Breast Cancer Awareness month, Ixcela, The Internal Fitness™ Company, in collaboration with Roper St. Francis Healthcare, today announced the Ixcela Cancer Support Program.
Existing standard chemoradiation superior to deintensification approaches for HPV-related oropharyngeal cancer
Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal cancer to prevent long-term side effects halted a large, randomized phase II/III trial after patients in the control arm reached a record high, two-year progression-free survival rate of 98%.
Histotripsy liver tumor trial successful, early clinical adoption recommended
The #HOPE4LIVER trials, testing the safety efficacy of histotripsy as a treatment for primary and metastatic liver tumors, met its goals for technical success and safety. An expert is quoted explaining the results.
Elle Macpherson says she refused chemotherapy after breast cancer diagnosis. Here’s what oncologists think.
After being diagnosed with breast cancer seven years ago, Elle Macpherson made a controversial choice: She refused chemotherapy, the model has revealed in her new memoir, Elle: Life, Lessons, and Learning to Trust Yourself. Macpherson did undergo a lumpectomy — surgery to remove…
Moffitt Researchers Reveal Key LAG3 Mechanisms That Could Transform Cancer Immunotherapy
Immune checkpoint inhibitors are a type of cancer treatment that helps the immune system attack cancer cells more effectively. One of the key proteins involved in this process is Lymphocyte Activation Gene-3 (LAG3), which suppresses the antitumor immune response.
Leading Computational Scientist and Oncology Researcher Elana Fertig, PhD, Appointed as New Director of the Institute for Genome Sciences at the University of Maryland School of Medicine
University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD, announced today the appointment of Elana J. Fertig, PhD, FAIMBE, as the new Director of the School’s Institute for Genome Sciences (IGS).
Small molecules, big impact: advancing immune checkpoint inhibitors for cancer
Recent research highlights an approach in cancer therapy with small molecule drugs targeting immune checkpoints. These innovative drugs overcome the limitations of antibody-based inhibitors, such as poor tissue permeability and high production costs.
Chulalongkorn Organized “Cutting-edge Nanotechnologies for Good Health and Well-being” International Conference for Alternative Cancer Treatment
Chulalongkorn University organized an international academic conference titled “Cutting-edge Nanotechnologies for Good Health and Well-being” to present nanotechnology innovations as new alternatives for cancer treatment.
Targeting cancer with precision: neoantigen vaccines show promise
In an elegant fusion of science and medicine, neoantigen cancer vaccines are emerging as a formidable strategy in the battle against cancer. These vaccines, a testament to the power of personalized medicine, target cancer’s unique protein signatures, rallying the immune system for a precise and potent attack.
Demystifying APE1: New findings on direct activation of ATM signaling by DNA single-strand breaks
Whereas ATM signaling is well known to be activated by DNA doubles-strand breaks, this study provides new evidence that ATM signaling is directly activated by DNA single-strand breaks and activated and regulated by APE1 in eukaryotic systems.
MD Anderson and collaborators to launch project studying T cells on International Space Station
The University of Texas MD Anderson Cancer Center and collaborators are initiating a research project that will send T cells to the International Space Station (ISS) to study the effects of prolonged microgravity on cell differentiation, activation, memory and exhaustion.
FAU Researcher Receives Grant to Personalize Radiation Therapy for Cancer
While chemotherapy has advanced in personalization, personalized radiation therapy for cancer remains underdeveloped. A new project will use AI, in particular, deep reinforcement learning, to analyze multimodal data, and enhance cancer characterization and treatment to ultimately improve patient outcomes. Using personal health data, genetic information about the tumor, and patient treatment and follow-up data, digital twins will simulate diagnoses and treatment options to help physicians choose the most effective treatments and monitor responses over time.
Anthony Sung, MD, named director of Center for Survivorship and Patient-Oriented Research
Anthony Sung, MD, has been named the A. Drue Jennings Professor in Medical Oncology and the director of the Center for Survivorship and Patient-Oriented Research at The University of Kansas Cancer Center.
New Survey from NCCN Finds Cancer Drug Shortage Management Remains a Moving Target, Impacting Clinical Trials
NCCN shares new data on continued high prevalence for cancer drug shortages in the United States. In the latest survey, carboplatin and cisplatin shortages fell to 11% and 7% respectively, but 89% of centers surveyed continue to report shortages for at least one type of systemic therapy; 75% are experiencing two or more drug shortages.
FDA approves immunotherapy drug combo for non-muscle invasive bladder cancer after UCLA-led research shows improved outcomes for patients
The FDA approval was based on results of the QUILT 3.032 clinical trial, which was led by Dr. Karim Chamie, associate professor urology at the David Geffen School of Medicine at UCLA and a researcher at the UCLA Health Jonsson Comprehensive Cancer Center.
Borderplex Family Sparks Chain Reaction of Philanthropy After Supporting New Cancer Patient Fund with a Generous Gift
“Support is the most important part of cancer treatment,” says El Paso resident Rosario De Anda, who was diagnosed with breast cancer. “When I started to feel that sense of hope, I began to lose the fear. It made me want to live and push forward.” she adds.
NCCN Updates Treatment Recommendations for Breast, Colorectal, Lung, and other Cancer Types Based on Emerging Evidence
Recent NCCN Guidelines updates—along with the supporting evidence—will be presented during the NCCN 2024 Annual Conference held in Orlando, Florida April 5-7, and simultaneously online. Visit NCCN.org/conference to learn more and register.
LJI welcomes new faculty member Miguel Reina-Campos, Ph.D.
Cancer researcher Miguel Reina-Campos, Ph.D., has joined the faculty of La Jolla Institute for Immunology (LJI) as an Assistant Professor to lead the Laboratory of Tissue Immune Networks. His laboratory at LJI aims to investigate the basis of CD8+ T cell tissue immunity to improve life-saving cancer immunotherapies.
New tumor spatial mapping tool will help clinicians assess aggressiveness of cancer and personalize treatment
Scientists have developed a new AI tool that maps the function of proteins in a cancerous tumour, enabling clinicians to decide how to target treatment in a more precise way.
Researchers Discover Why One Type of Chemotherapy Works Best in Bladder Cancer
Tisch Cancer Institute researchers discovered that a certain type of chemotherapy improves the immune system’s ability to fight off bladder cancer, particularly when combined with immunotherapy, according to a study published in Cell Reports Medicine in January.
New Research Shows Patients Receiving Cancer Treatment Understand Health Insurance Basics; Important Knowledge Gaps Remain
A new study by researchers at the American Cancer Society showed among patients receiving outpatient cancer treatment in two sites, most people could understand basic health insurance terms, such as premiums and deductibles.
Thailand Hub of Talent for Cancer Immunotherapy International Conference
The Faculty of Medicine, Chulalongkorn University, cordially invites all to attend the “Thailand Hub of Talent for Cancer Immunotherapy International Conference: Portal to Global Collaboration for Next Generation Cell and Gene Therapy Development” on November 16-17, 2023 at Bhumisiri Mangklanusorn Building, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Mount Sinai Awarded $3.4 Million to Study Prostate Cancer in People With HIV
The National Cancer Institute has awarded the Icahn School of Medicine at Mount Sinai a $3.4 million grant to create a model that identifies the best prostate cancer treatment for people with HIV.
Tip Sheet: Personalizing cancer treatment, cancer and the LGBTQ+ community – and expanded Medicaid coverage linked to increased participation in cancer clinical trials
SEATTLE — Sept. 6, 2023 — Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news.Reporting on wildfire smoke? Fred Hutch clinicians and researchers are available to their expertise.
Transforming Cancer Diagnosis and Treatment with Cerium/Lanthanum-134
Actinium-targeted alpha radiotherapy is a promising approach for treating metastatic cancers, including prostate cancer. However, therapeutic substances labeled with actinium-225 have limits on how they can be imaged, a step that allows doctors to plan treatments. This study examined the performance of cerium/lanthanum-134 as a surrogate imaging material for Ac-225.
Canadian researchers find radiation not necessary for patients with low-risk breast cancer
Researchers from McMaster University, BC Cancer, Hamilton Heath Sciences, and the University of British Columbia have found some women with early-stage, low-risk breast cancer may not need radiotherapy after breast conserving surgery.
Study finds improved survival for incurable brain tumor, providing ‘a crack in the armor’
For the first time, researchers have found a potential drug candidate that improved outcomes for patients with a type of childhood brain tumor for which there are no effective treatments. The compound, called ONC201, nearly doubled survival for patients with diffuse midline glioma (DMG) or diffuse intrinsic pontine glioma (DIPG), compared to previous patients.
Understanding Epigenetic Changes in Glial Cells May be Key to Combatting Brain Tumors
Gliomas are incurable brain tumors. Researchers are trying to unlock the mysteries of how they originate from normal cells, which may lead to better treatments.
Killing Cancer in a Flash
FLASH is a targeted radiation therapy that kills tumor cells while sparing healthy tissue and delivers a short, intense burst of radiation in a single appointment. Corie Ralston from Lawrence Berkeley National Laboratory will present her team’s research using X-ray footprinting mass spectrometry to investigate the mechanisms that make FLASH a powerful cancer killer at ACA’s 73rd annual meeting, July 7-11.
Faster, safer target prep
Oak Ridge National Laboratory researchers have developed a method to simplify one step of radioisotope production — and it’s faster and safer.
Pharmacologist: Cancer drug shortage is delaying lifesaving treatments
This year, an estimated 2 million Americans will be diagnosed with cancer. Now, a New York Institute of Technology pharmacology expert contends that these patients’ realities could grow increasingly harsher, as a monthslong shortage of chemotherapy drugs continues. Low supplies of…
Pharmacists give perspective on chemotherapy drug shortages
As U.S. cancer centers continue to navigate shortages of certain chemotherapy drugs, many patients likely fear whether they will be able to secure regular access to their treatment medications. Julie Kennerly Shah, PharmD, associate director of pharmacy, at The Ohio…
NCCN Releases Statement Addressing Ongoing Chemotherapy Shortages; Shares Survey Results Finding More than 90% of Cancer Centers are Impacted
National Comprehensive Cancer Network’s Department of Policy and Advocacy calls on Federal Government, pharmaceutical industry, providers, and payers to work together on solutions, as 93% of cancer centers surveyed report a shortage of carboplatin and 70% report shortages for cisplatin; two medications that are used in combination to cure many types of cancer.
Tunable Bonds: A Step Towards Targeted At-211 Cancer Therapy
The astatine isotope astatine-211 (At-211) shows promise as a cancer therapy, but scientists know little about how it interacts with chemicals. Researchers have now discovered a new tunable bonding interaction between At-211 and a class of chemicals known as ketones. This discovery has the potential to improve cancer therapy drugs by linking At-211 to cancer targeting molecules.
Virginia Tech researchers join together on cancer prevention, diagnosis and treatment
May is a month to recognize the importance of cancer research, with both Brain Tumor Awareness Month and National Cancer Research Month taking center stage. Virginia Tech’s Fralin Biomedical Research Institute at VTC is dedicated to advancing our understanding of cancer and developing new ways to treat and prevent it. Teams of investigators are working to uncover the molecular mechanisms that drive cancer growth, migration, and metastasis.
A combination of TLR9 and STING agonists induces potent neopeptide-specific T cell immunity and improves ICB efficacy in tumor models
Immunotherapies such as immune checkpoint blockade (ICB) therapies have been developed in the last years as a promising strategy for the treatment of cancer, however there remains a need to improve their efficacy. The most critical factor that affects the…
Promising Medical Isotope Made and Processed at Brookhaven Lab
Thanks to a recent upgrade to the medical isotope facilities at Brookhaven National Laboratory, actinium-225 (Ac-225), an isotope that shows great promise for treating cancer, can now be produced, purified, and shipped ready for use directly from the Lab. The first shipment left Brookhaven in mid-March.